CA2253632C - Compositions and methods for treating cancers and pathogen infections using antigen-presenting cells loaded with rna - Google Patents
Compositions and methods for treating cancers and pathogen infections using antigen-presenting cells loaded with rna Download PDFInfo
- Publication number
- CA2253632C CA2253632C CA002253632A CA2253632A CA2253632C CA 2253632 C CA2253632 C CA 2253632C CA 002253632 A CA002253632 A CA 002253632A CA 2253632 A CA2253632 A CA 2253632A CA 2253632 C CA2253632 C CA 2253632C
- Authority
- CA
- Canada
- Prior art keywords
- rna
- tumor
- apc
- derived
- pathogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 173
- 238000000034 method Methods 0.000 title claims abstract description 139
- 210000000612 antigen-presenting cell Anatomy 0.000 title claims abstract description 119
- 244000052769 pathogen Species 0.000 title claims abstract description 103
- 230000001717 pathogenic effect Effects 0.000 title claims abstract description 100
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 125
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 60
- 230000005740 tumor formation Effects 0.000 claims abstract description 13
- 210000002540 macrophage Anatomy 0.000 claims abstract description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 370
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 84
- 239000000427 antigen Substances 0.000 claims description 55
- 102000036639 antigens Human genes 0.000 claims description 55
- 108091007433 antigens Proteins 0.000 claims description 55
- 238000000338 in vitro Methods 0.000 claims description 41
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 29
- 210000004881 tumor cell Anatomy 0.000 claims description 28
- 230000004044 response Effects 0.000 claims description 27
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- 241000700605 Viruses Species 0.000 claims description 16
- 239000002299 complementary DNA Substances 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 15
- 210000001519 tissue Anatomy 0.000 claims description 14
- 230000032258 transport Effects 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 206010070834 Sensitisation Diseases 0.000 claims description 12
- 230000000890 antigenic effect Effects 0.000 claims description 12
- 230000008313 sensitization Effects 0.000 claims description 12
- 230000006052 T cell proliferation Effects 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 102000004127 Cytokines Human genes 0.000 claims description 10
- 108090000695 Cytokines Proteins 0.000 claims description 10
- 239000002955 immunomodulating agent Substances 0.000 claims description 10
- 229940121354 immunomodulator Drugs 0.000 claims description 10
- 230000006698 induction Effects 0.000 claims description 10
- 201000001441 melanoma Diseases 0.000 claims description 10
- -1 cationic lipid Chemical class 0.000 claims description 9
- 230000002584 immunomodulator Effects 0.000 claims description 9
- 230000035755 proliferation Effects 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 8
- 231100000433 cytotoxic Toxicity 0.000 claims description 8
- 230000001472 cytotoxic effect Effects 0.000 claims description 8
- 238000013518 transcription Methods 0.000 claims description 8
- 230000035897 transcription Effects 0.000 claims description 8
- 238000002784 cytotoxicity assay Methods 0.000 claims description 7
- 231100000263 cytotoxicity test Toxicity 0.000 claims description 7
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 6
- 230000028327 secretion Effects 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 241000588914 Enterobacter Species 0.000 claims description 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 4
- 241000712079 Measles morbillivirus Species 0.000 claims description 4
- 241000711386 Mumps virus Species 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 208000000474 Poliomyelitis Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 241000710799 Rubella virus Species 0.000 claims description 4
- 241000607142 Salmonella Species 0.000 claims description 4
- 241000607768 Shigella Species 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 210000002889 endothelial cell Anatomy 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 241001529453 unidentified herpesvirus Species 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 108020003217 Nuclear RNA Proteins 0.000 claims description 3
- 102000043141 Nuclear RNA Human genes 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 230000000139 costimulatory effect Effects 0.000 claims description 3
- 108091092330 cytoplasmic RNA Proteins 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 210000001163 endosome Anatomy 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims description 2
- 230000010189 intracellular transport Effects 0.000 claims description 2
- 210000003712 lysosome Anatomy 0.000 claims description 2
- 230000001868 lysosomic effect Effects 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 108020004513 Bacterial RNA Proteins 0.000 claims 1
- 238000012408 PCR amplification Methods 0.000 claims 1
- 108020000999 Viral RNA Proteins 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 abstract description 7
- 108010058846 Ovalbumin Proteins 0.000 description 39
- 241000699670 Mus sp. Species 0.000 description 31
- 229940092253 ovalbumin Drugs 0.000 description 25
- 238000002360 preparation method Methods 0.000 description 20
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 238000002255 vaccination Methods 0.000 description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 206010061289 metastatic neoplasm Diseases 0.000 description 12
- 230000001394 metastastic effect Effects 0.000 description 11
- 239000008188 pellet Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 210000004882 non-tumor cell Anatomy 0.000 description 10
- 238000011740 C57BL/6 mouse Methods 0.000 description 9
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 9
- 239000013614 RNA sample Substances 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 229910052693 Europium Inorganic materials 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000012636 effector Substances 0.000 description 7
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 102100034343 Integrase Human genes 0.000 description 5
- 101710203526 Integrase Proteins 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 239000012124 Opti-MEM Substances 0.000 description 5
- 238000002266 amputation Methods 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 239000008223 sterile water Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000003151 transfection method Methods 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 108091092236 Chimeric RNA Proteins 0.000 description 2
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 238000011510 Elispot assay Methods 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 2
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- PSHJFSXQZBLAMV-UHFFFAOYSA-K [Eu+3].CC(O)=O.CC(O)=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.NCCNCCN Chemical compound [Eu+3].CC(O)=O.CC(O)=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.NCCNCCN PSHJFSXQZBLAMV-UHFFFAOYSA-K 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 102000054766 genetic haplotypes Human genes 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000001531 micro-dissection Methods 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000001235 sensitizing effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 101100000858 Caenorhabditis elegans act-3 gene Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
- 101710116782 Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 101710124239 Poly(A) polymerase Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 241001441550 Zeiformes Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000012296 in situ hybridization assay Methods 0.000 description 1
- 238000003017 in situ immunoassay Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000003358 metastasis assay Methods 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229960000554 metrizamide Drugs 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- GUUBJKMBDULZTE-UHFFFAOYSA-M potassium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[K+].OCCN1CCN(CCS(O)(=O)=O)CC1 GUUBJKMBDULZTE-UHFFFAOYSA-M 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/77—Ovalbumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/640,444 | 1996-04-30 | ||
| US08/640,444 US5853719A (en) | 1996-04-30 | 1996-04-30 | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| PCT/US1997/007317 WO1997041210A1 (en) | 1996-04-30 | 1997-04-30 | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with rna |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2253632A1 CA2253632A1 (en) | 1997-11-06 |
| CA2253632C true CA2253632C (en) | 2008-12-16 |
Family
ID=42676767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002253632A Expired - Lifetime CA2253632C (en) | 1996-04-30 | 1997-04-30 | Compositions and methods for treating cancers and pathogen infections using antigen-presenting cells loaded with rna |
Country Status (11)
| Country | Link |
|---|---|
| US (9) | US5853719A (enExample) |
| EP (3) | EP0918848B1 (enExample) |
| JP (2) | JP3836151B2 (enExample) |
| AT (1) | ATE346912T1 (enExample) |
| AU (1) | AU724267B2 (enExample) |
| CA (1) | CA2253632C (enExample) |
| DE (1) | DE69737023T2 (enExample) |
| DK (1) | DK0918848T3 (enExample) |
| ES (1) | ES2277675T3 (enExample) |
| PT (1) | PT918848E (enExample) |
| WO (1) | WO1997041210A1 (enExample) |
Families Citing this family (129)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| US7585622B1 (en) * | 1996-10-01 | 2009-09-08 | Geron Corporation | Increasing the proliferative capacity of cells using telomerase reverse transcriptase |
| US6475789B1 (en) * | 1996-10-01 | 2002-11-05 | University Technology Corporation | Human telomerase catalytic subunit: diagnostic and therapeutic methods |
| IL129103A0 (en) * | 1996-10-01 | 2000-02-17 | Geron Corp | Human telomerase catalytic subunit and pharmaceutical compositions containing same |
| US6228640B1 (en) | 1997-02-07 | 2001-05-08 | Cem Cezayirli | Programmable antigen presenting cell of CD34 lineage |
| US6977073B1 (en) | 1997-02-07 | 2005-12-20 | Cem Cezayirli | Method for stimulating an immune response |
| US6251665B1 (en) | 1997-02-07 | 2001-06-26 | Cem Cezayirli | Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom |
| US20050169898A1 (en) * | 1997-04-15 | 2005-08-04 | Jianlin Gong | Cell fusions and methods of making and using the same |
| US20020041868A1 (en) * | 1997-04-15 | 2002-04-11 | Charles Nicolette | Cell fusions and methods of making and using the same |
| US7413864B2 (en) * | 1997-04-18 | 2008-08-19 | Geron Corporation | Treating cancer using a telomerase vaccine |
| US7622549B2 (en) * | 1997-04-18 | 2009-11-24 | Geron Corporation | Human telomerase reverse transcriptase polypeptides |
| US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| US6337200B1 (en) * | 1998-03-31 | 2002-01-08 | Geron Corporation | Human telomerase catalytic subunit variants |
| CA2347067C (en) | 1998-03-31 | 2013-09-17 | Geron Corporation | Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer |
| US7402307B2 (en) * | 1998-03-31 | 2008-07-22 | Geron Corporation | Method for identifying and killing cancer cells |
| US20030022854A1 (en) * | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| US20040247662A1 (en) * | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
| FR2785542B1 (fr) * | 1998-11-06 | 2001-02-09 | Pf Medicament | UTILISATION D'UNE PROTEINE OmpA D'ENTEROBACTERIE, POUR LE CIBLAGE SPECIFIQUE D'UNE SUBSTANCE BIOLOGIQUEMENT ACTIVE QUI LUI EST ASSOCIEE VERS LES CELLULES PRESENTATRICES D'ANTIGENES TELLES QUE LES CELLULES DENDRITIQUES HUMAINES |
| US7713739B1 (en) * | 2000-11-17 | 2010-05-11 | Novartis Vaccines And Diagnostics, Inc. | Microparticle-based transfection and activation of dendritic cells |
| US7015204B1 (en) * | 1999-10-07 | 2006-03-21 | Cornell Research Foundation, Inc. | Protective immunity or immunological tolerance induced with RNA particularly total cellular RNA |
| US7541184B2 (en) | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6783939B2 (en) * | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
| EP1436413A2 (en) * | 2000-10-24 | 2004-07-14 | Whitehead Institute For Biomedical Research | Response of dendritic cells to a diverse set of pathogens |
| AU2002240197A1 (en) * | 2001-02-01 | 2002-08-12 | Tanox, Inc. | Methods to generate and identify monoclonal antibodies to a large number of human antigens |
| DE10112851C1 (de) | 2001-03-16 | 2002-10-10 | Gsf Forschungszentrum Umwelt | Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen |
| EP1390076A4 (en) * | 2001-04-27 | 2004-12-15 | Xcyte Therapies Inc | Maturation of antigen-presenting cells with activated cells |
| GB0111015D0 (en) * | 2001-05-04 | 2001-06-27 | Norsk Hydro As | Genetic material |
| ES2340532T3 (es) | 2001-06-05 | 2010-06-04 | Curevac Gmbh | Arnm con un contenido g/c aumentado que codifica para un antigeno bacteriano y utilizacion del mismo. |
| EP1432791B2 (en) * | 2001-09-06 | 2013-10-23 | Alphavax, Inc. | Alphavirus replicon vector systems |
| EP1442125A4 (en) * | 2001-10-04 | 2004-12-08 | Carlos Estuard Aguilar-Cordova | CHIMERAL VIRUS VECTORS FOR GENE THERAPY |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| CN1665523A (zh) * | 2002-07-05 | 2005-09-07 | 杜克大学 | 血管免疫疗法 |
| US20040161417A1 (en) * | 2002-08-14 | 2004-08-19 | Eli Gilboa | Method of enhancing CD4+ T cell responses |
| ES2375299T3 (es) | 2002-09-12 | 2012-02-28 | Oncotherapy Science, Inc. | Péptidos kdr y vacunas que los contienen. |
| AU2003296439B2 (en) * | 2002-12-10 | 2009-05-07 | Argos Therapeutics, Inc. | In situ maturation of dendritic cells |
| CA2509973C (en) * | 2002-12-13 | 2013-02-26 | Alphavax, Inc. | Multi-antigenic alphavirus replicon particles and methods |
| AU2003297041B2 (en) * | 2002-12-13 | 2009-02-26 | Alphavax, Inc. | Alphavirus particles and methods for preparation |
| EP2557164A1 (en) * | 2003-02-18 | 2013-02-13 | Kevin M. Slawin | Induced activation in dendritic cells |
| US20060134067A1 (en) * | 2003-02-18 | 2006-06-22 | Maxcyte, Inc. | Loading of cells with antigens by electroporation |
| JP2006518219A (ja) * | 2003-02-18 | 2006-08-10 | マックスサイト インコーポレーティッド | 電気穿孔法による細胞への抗原の負荷方法 |
| EP1608762B1 (en) * | 2003-03-20 | 2014-01-08 | Alphavax, Inc. | Improved alphavirus replicons and helper constructs |
| ATE432285T1 (de) * | 2003-07-11 | 2009-06-15 | Alphavax Inc | Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren |
| DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
| CN1882603A (zh) * | 2003-11-25 | 2006-12-20 | 阿哥斯医疗公司 | mRNA转染的抗原呈递细胞 |
| US20050181035A1 (en) * | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
| EP1730263A4 (en) * | 2004-03-02 | 2008-01-23 | Tsuneya Ohno | METHODS AND COMPOSITIONS RELATING TO HYBRID CELL VACCINES FOR TREATMENT AND CANCER PREVENTION |
| AU2005245956B2 (en) * | 2004-05-18 | 2011-05-19 | Alphavax, Inc. | TC-83-derived alphavirus vectors, particles and methods |
| US20080293581A1 (en) * | 2004-05-24 | 2008-11-27 | Rogler Charles E | Rna Expression Microarrays |
| CA2504451A1 (en) * | 2004-08-10 | 2006-02-10 | Geron Corporation | Dendritic cell vaccines for treating cancer made from embryonic stem cells |
| PL1794327T3 (pl) | 2004-09-14 | 2017-04-28 | Argos Therapeutics, Inc. | Niezależna od szczepu amplifikacja patogenów i szczepionki przeciwko nim |
| US20060216269A1 (en) * | 2004-09-17 | 2006-09-28 | Kenichiro Hasumi | Dendritic cell tumor injection (DCTI) therapy |
| US8076132B2 (en) | 2004-09-17 | 2011-12-13 | Hasumi International Research Foundation | Dendritic cell tumor injection (DCTI) therapy |
| GB0501129D0 (en) * | 2005-01-19 | 2005-02-23 | Ribostem Ltd | Method of treatment by administration of RNA |
| EP2325305B1 (en) | 2005-02-25 | 2014-02-12 | Oncotherapy Science, Inc. | Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides |
| SI2095822T1 (sl) | 2005-02-28 | 2013-12-31 | Oncotherapy Science, Inc. | Peptidi epitopov, izpeljani iz receptorja 1 vaskularnega endotelijskega rastnega faktorja, in cepiva, ki vsebujejo te peptide |
| ES2650569T3 (es) | 2005-04-08 | 2018-01-19 | Argos Therapeutics, Inc. | Composiciones de células dendríticas y métodos |
| HUE027330T2 (en) | 2005-07-27 | 2016-09-28 | Oncotherapy Science Inc | The TOM34 gene for colon cancer |
| AU2006304573B2 (en) | 2005-10-17 | 2012-05-24 | Sloan Kettering Institute For Cancer Research | WT1 HLA class II-binding peptides and compositions and methods comprising same |
| PL2010209T3 (pl) | 2006-04-10 | 2017-04-28 | Sloan Kettering Inst For Cancer Res | Immunogeniczne peptydy WT-1 i sposoby ich użycia |
| CA2649325C (en) | 2006-04-14 | 2019-01-08 | Epicentre Technologies Corporation | Kits and methods for generating 5' capped rna |
| SI2051987T1 (sl) | 2006-08-18 | 2015-02-27 | Argos Therapeutics, Inc. | Uporaba cd83 v kombinacijskih terapijah |
| KR101454287B1 (ko) | 2006-10-17 | 2014-11-04 | 온코세라피 사이언스 가부시키가이샤 | Ｍｐｈｏｓｐｈ1 또는 ｄｅｐｄｃ1 폴리펩티드를 발현하는 암에 대한 펩티드 백신 |
| EP2465510B1 (en) * | 2006-10-19 | 2018-11-28 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof |
| WO2008055354A1 (en) * | 2006-11-10 | 2008-05-15 | Université de Montréal | Rna-loaded dendritic cell compositions for eliciting cd4+ t cell help and related methods |
| TWI615403B (zh) | 2007-02-21 | 2018-02-21 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| TW201425333A (zh) | 2007-04-11 | 2014-07-01 | Oncotherapy Science Inc | 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗 |
| NZ582495A (en) | 2007-06-21 | 2012-05-25 | Alphavax Inc | Promoterless cassettes for expression of alphavirus structural proteins |
| SG183717A1 (en) | 2007-08-20 | 2012-09-27 | Oncotherapy Science Inc | Foxm1 peptide and medicinal agent comprising the same |
| US8513208B2 (en) * | 2008-02-28 | 2013-08-20 | Argos Therapeutics, Inc. | Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection |
| EP3156069B8 (en) | 2008-06-20 | 2020-10-21 | Duke University | Compositions, methods, and kits for eliciting an immune response |
| US20100203067A1 (en) | 2008-09-22 | 2010-08-12 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters |
| WO2010058023A1 (en) | 2008-11-24 | 2010-05-27 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh | High affinity t cell receptor and use thereof |
| TWI500932B (zh) | 2008-12-05 | 2015-09-21 | Oncotherapy Science Inc | Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗 |
| US8728806B2 (en) | 2008-12-06 | 2014-05-20 | The Board Of Regents, The University Of Texas System | Methods and compositions related to Th-1 dendritic cells |
| TWI469791B (zh) | 2009-02-18 | 2015-01-21 | Oncotherapy Science Inc | Ｆｏｘｍ１胜肽以及含此胜肽之疫苗 |
| CN105601725B (zh) | 2009-03-18 | 2019-08-09 | 肿瘤疗法科学股份有限公司 | Neil3肽及包含它的疫苗 |
| TWI507204B (zh) | 2009-05-26 | 2015-11-11 | Oncotherapy Science Inc | Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗 |
| TW201136604A (en) | 2009-12-14 | 2011-11-01 | Oncotherapy Science Inc | TMEM22 peptides and vaccines including the same |
| MX344579B (es) | 2010-03-11 | 2016-12-19 | Oncotherapy Science Inc * | Peptidos hjurp y vacunas que incluyen los mismos. |
| TWI538685B (zh) | 2010-04-02 | 2016-06-21 | 腫瘤療法 科學股份有限公司 | Ｅｃｔ２胜肽及含此胜肽之疫苗 |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| SI3590949T1 (sl) | 2010-10-01 | 2022-09-30 | Modernatx, Inc. | Ribonukleinske kisline, ki vsebujejo N1-metil-psevdouracil, in njihove uporabe |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| EP2557089A2 (en) | 2011-07-15 | 2013-02-13 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Compositions and methods for immunomodulation |
| US9458447B2 (en) | 2011-08-12 | 2016-10-04 | Oncotherapy Science, Inc. | MPHOSPH1 peptides and vaccines including the same |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| US9427461B2 (en) | 2011-10-28 | 2016-08-30 | Oncotherapy Science, Inc. | TOPK peptides and vaccines including the same |
| RU2649364C2 (ru) | 2011-12-16 | 2018-04-02 | Модерна Терапьютикс, Инк. | Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты |
| EP2802347B1 (en) | 2012-01-13 | 2019-01-09 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and methods of use thereof |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| EP3520821A1 (en) | 2012-04-02 | 2019-08-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| WO2014010231A1 (en) | 2012-07-10 | 2014-01-16 | Oncotherapy Science, Inc. | Kif20a epitope peptides for th1 cells and vaccines containing the same |
| SI2922554T1 (sl) | 2012-11-26 | 2022-06-30 | Modernatx, Inc. | Terminalno modificirana RNA |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| CA2898099C (en) | 2013-01-15 | 2025-09-16 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and methods of use thereof |
| US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| TWI658049B (zh) | 2013-03-12 | 2019-05-01 | 腫瘤療法 科學股份有限公司 | Ｋｎｔｃ２胜肽及含此胜肽之疫苗 |
| EP2968502B1 (en) | 2013-03-14 | 2020-08-26 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| DK3004329T3 (da) | 2013-06-05 | 2020-05-18 | Bellicum Pharmaceuticals Inc | Fremgangsmåder til induktion af delvis apoptose under anvendelse af caspasepolypeptider |
| HK1226299A1 (zh) | 2013-09-24 | 2017-09-29 | Duke University | 用於诱发免疫反应的组合物、方法及工具 |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
| AU2015218396A1 (en) | 2014-02-14 | 2016-08-11 | Bellicum Pharmaceuticals, Inc. | Methods for activating T cells using an inducible chimeric polypeptide |
| US9610358B2 (en) * | 2014-04-17 | 2017-04-04 | Marker Gene Technologies, Inc | Targeted pharmacological chaperones |
| WO2016014613A1 (en) * | 2014-07-22 | 2016-01-28 | The Trustees Of The University Of Pennsylvania | Compositions and methods for cancer immunotherapy |
| AU2015300260B2 (en) | 2014-08-04 | 2020-01-02 | Oncotherapy Science, Inc. | URLC10-derived peptide and vaccine containing same |
| KR20220155610A (ko) | 2014-08-04 | 2022-11-23 | 온코세라피 사이언스 가부시키가이샤 | Koc1-유래 펩티드 및 이를 포함하는 백신 |
| KR20170040315A (ko) | 2014-08-04 | 2017-04-12 | 온코세라피 사이언스 가부시키가이샤 | Cdca1-유래 펩티드 및 이를 포함하는 백신 |
| WO2016036746A1 (en) | 2014-09-02 | 2016-03-10 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides |
| KR20170078619A (ko) * | 2014-09-17 | 2017-07-07 | 더 존스 홉킨스 유니버시티 | 항원-특이적 t 세포 식별, 농축, 및/또는 증식을 위한 시약 및 방법 |
| HK1243631A1 (zh) * | 2014-10-27 | 2018-07-20 | Fred Hutchinson Cancer Research Center | 用於提高过继细胞免疫疗法效力的组合物和方法 |
| EP3215522B1 (en) | 2014-11-03 | 2021-12-01 | Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum | T cell receptors directed against bob1 and uses thereof |
| JP2018090491A (ja) * | 2015-04-01 | 2018-06-14 | 株式会社細胞治療技術研究所 | 癌ワクチンの製造方法、及び癌ワクチン |
| US11090332B2 (en) * | 2015-05-21 | 2021-08-17 | Regen BioPharma, Inc. | Antigen specific mRNA cellular cancer vaccines |
| JP6666094B2 (ja) * | 2015-09-15 | 2020-03-13 | 株式会社東芝 | 吸着支持装置、および物品把持装置 |
| CN108137652B (zh) | 2015-10-08 | 2021-08-03 | 肿瘤疗法科学股份有限公司 | Foxm1衍生的肽和包含它们的疫苗 |
| US11780934B2 (en) | 2016-02-05 | 2023-10-10 | Institut Pasteur | Use of inhibitors of ADAM12 as adjuvants in tumor therapies |
| JP7033549B2 (ja) | 2016-05-04 | 2022-03-10 | フレッド ハッチンソン キャンサー リサーチ センター | 細胞に基づくネオ抗原ワクチンおよびその使用 |
| CN109414023A (zh) * | 2016-06-29 | 2019-03-01 | 杜克大学 | 用嵌合脊髓灰质炎病毒激活抗原呈递细胞的组合物和方法 |
| WO2019135701A1 (en) * | 2018-01-05 | 2019-07-11 | Nilsson Rolf Jonas Andreas | Endogenous tumor-derived circular rna and proteins thereof for use as vaccine |
| TW202023581A (zh) | 2018-08-02 | 2020-07-01 | 日商腫瘤療法 科學股份有限公司 | 來自cdca1的胜肽及含有此的疫苗 |
| US20250144143A1 (en) * | 2023-11-06 | 2025-05-08 | Immunitybio, Inc. | Virally Educated T cells |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4918164A (en) * | 1987-09-10 | 1990-04-17 | Oncogen | Tumor immunotherapy using anti-idiotypic antibodies |
| US5256536A (en) | 1990-11-09 | 1993-10-26 | Syntex (U.S.A.) Inc. | Nucleotide probe for Neisseria gonrrhoeae |
| US5662907A (en) * | 1992-08-07 | 1997-09-02 | Cytel Corporation | Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes |
| US6696061B1 (en) * | 1992-08-11 | 2004-02-24 | President And Fellows Of Harvard College | Immunomodulatory peptides |
| JPH08502244A (ja) | 1992-08-11 | 1996-03-12 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 免疫調節ペプチド |
| DE4233430A1 (de) * | 1992-10-05 | 1994-04-07 | Basf Ag | Verfahren zur Herstellung von 4-Hydroxymethyltetrahydropyran |
| US5830877A (en) | 1993-08-26 | 1998-11-03 | The Regents Of The University Of California | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory |
| CA2192655A1 (en) * | 1994-06-14 | 1995-12-21 | Edgar G. Engleman | Methods for in vivo t cell activation by antigen-pulsed dendritic cells |
| US5827642A (en) * | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US5831068A (en) | 1995-08-21 | 1998-11-03 | Duke University | Method to increase the density of antigen on antigen presenting cells |
| US5853719A (en) * | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| US6130087A (en) * | 1996-10-07 | 2000-10-10 | Fordham University | Methods for generating cytotoxic T cells in vitro |
| US6228640B1 (en) * | 1997-02-07 | 2001-05-08 | Cem Cezayirli | Programmable antigen presenting cell of CD34 lineage |
| US6831068B2 (en) * | 2002-02-13 | 2004-12-14 | Abbott Laboratories | Macrolide antibacterial compounds |
| DE102004055330A1 (de) | 2004-11-16 | 2006-05-24 | Bosch Rexroth Aktiengesellschaft | Verfahren und Vorrichtung zum Betreiben eines Netzwerkes |
-
1996
- 1996-04-30 US US08/640,444 patent/US5853719A/en not_active Expired - Lifetime
-
1997
- 1997-04-30 ES ES97922581T patent/ES2277675T3/es not_active Expired - Lifetime
- 1997-04-30 EP EP97922581A patent/EP0918848B1/en not_active Expired - Lifetime
- 1997-04-30 AT AT97922581T patent/ATE346912T1/de active
- 1997-04-30 EP EP06015438.2A patent/EP1721987B1/en not_active Expired - Lifetime
- 1997-04-30 WO PCT/US1997/007317 patent/WO1997041210A1/en not_active Ceased
- 1997-04-30 US US09/171,916 patent/US7105157B1/en not_active Expired - Fee Related
- 1997-04-30 AU AU28213/97A patent/AU724267B2/en not_active Expired
- 1997-04-30 EP EP10010076A patent/EP2298927A3/en not_active Withdrawn
- 1997-04-30 DE DE69737023T patent/DE69737023T2/de not_active Expired - Lifetime
- 1997-04-30 PT PT97922581T patent/PT918848E/pt unknown
- 1997-04-30 CA CA002253632A patent/CA2253632C/en not_active Expired - Lifetime
- 1997-04-30 DK DK97922581T patent/DK0918848T3/da active
- 1997-04-30 JP JP53921097A patent/JP3836151B2/ja not_active Expired - Lifetime
-
1998
- 1998-05-06 US US09/073,819 patent/US6306388B1/en not_active Expired - Lifetime
-
1999
- 1999-04-30 US US09/302,329 patent/US6387701B1/en not_active Expired - Lifetime
-
2000
- 2000-09-22 US US09/667,319 patent/US6670186B1/en not_active Expired - Lifetime
-
2001
- 2001-06-07 US US09/875,264 patent/US7101705B2/en not_active Expired - Lifetime
-
2005
- 2005-10-17 US US11/250,546 patent/US7601343B2/en not_active Expired - Fee Related
-
2006
- 2006-05-08 JP JP2006129005A patent/JP3955311B2/ja not_active Expired - Lifetime
-
2009
- 2009-09-01 US US12/585,028 patent/US8263066B2/en not_active Expired - Fee Related
-
2012
- 2012-07-20 US US13/554,938 patent/US9115360B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2253632C (en) | Compositions and methods for treating cancers and pathogen infections using antigen-presenting cells loaded with rna | |
| Boczkowski et al. | Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. | |
| US5831068A (en) | Method to increase the density of antigen on antigen presenting cells | |
| Porgador et al. | Induction of antitumor immunity using bone marrow-generated dendritic cells. | |
| CA2347067C (en) | Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer | |
| EP1210430B1 (en) | Muc-1 derived peptides | |
| CN103570818B (zh) | 肿瘤抗原性多肽及其作为肿瘤疫苗的用途 | |
| Hermans et al. | Tumor-peptide-pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge | |
| CN103570821A (zh) | 粘蛋白-1抗原性多肽及其作为肿瘤疫苗的用途 | |
| HK1154631A (en) | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with rna | |
| US20040161417A1 (en) | Method of enhancing CD4+ T cell responses | |
| JPWO2003000894A1 (ja) | ポリヌクレオチドワクチン | |
| EP1625218A2 (en) | Heparanase-derived peptides for vaccination of tumor patients | |
| CN101168064A (zh) | 重组人胰腺癌黏液蛋白核心肽dna疫苗 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20170501 |